Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
LYRA vs PLRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PLRX Captures Overall Composite Edge (39.0 SELL vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars
PLRX Overall Winner
6-Pillar Tally: LYRA 3 – 2 PLRX (1 Tie)
Matrix Metrics: LYRA 3 – 4 PLRX
As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (39.0/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus PLRX at $0.66 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (-100.0% vs. -87.2% YoY).
- Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile PLRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About LYRA vs PLRX
LYRA
Lyra Therapeutics, Inc. Common Stock
$0.49
-62.5% 1D
Market Cap
$2.3M
TTM Revenue
$600,000
Forward P/E
N/M
Beta / 30D Vol
0.33β · 248% Vol
Unified Composite Score
52.2
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
PLRX
Head-to-Head Winner
Pliant Therapeutics, Inc. Common Stock
$0.66
-5.16% 1D
Market Cap
$43.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.93β · 37% Vol
Unified Composite Score
39.0
SELL
Tech 25.0
Fund 43.0
Flow 63.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (LYRA 3 – 2 PLRX)
1. Valuation Multiples
LYRA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
N/M
2. Growth & Scale
LYRA
Revenue Growth (YoY)
-87.2%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$600,000
N/A
Market Cap
$2.3M
$43.2M
3. Profitability & Quality
PLRX
Gross Margin
N/A
N/A
Operating Margin
-25032.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-404.5%
-50.3%
4. Balance Sheet & Cash Flow
LYRA
Cash Generation (TTM)
-$32M EBITDA
-$71M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
-404.5% ROE
$3.9M Net Debt (0.20x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PLRX
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
12.8% (4th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: LYRA (3) vs PLRX (4)| Institutional Metric | LYRA | PLRX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.3M | $43.2M | PLRX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -87.2% | -100.0% | LYRA | |
| Operating Margin (TTM) | -25032.0% | 0.0% | PLRX | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -404.5% | -50.3% | PLRX | |
| 52-Week Range Position | 1% ($0–$38) | 0% ($1–$2) | LYRA | |
| Beta / 30D Volatility | 0.33β · 248% Vol | 0.93β · 37% Vol | PLRX | |
| Unified Institutional Score | 52.2 / 100 (HOLD) | 39.0 / 100 (SELL) | LYRA | |
| Trailing 12M Revenue (USD) | $600,000 | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M EBITDA (-404.5% ROE) | -$71M ($3.9M Net Debt (0.20x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PLRX +78.43 pp
3M Horizon
PLRX +86.86 pp
6M Horizon
PLRX +65.12 pp
1Y Horizon
PLRX +65.12 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | PLRX Revenue | LYRA Op. Margin | PLRX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $60M | N/A | -2.2% | PLRX |
| FY2020 | N/A | $40M | N/A | -99.6% | PLRX |
| FY2021 | $0M | $10M | -15303.5% | -1288.1% | PLRX |
| FY2022 | $0M | $10M | -4131.0% | -1313.4% | PLRX |
| FY2023 | $0M | $0M | -4308.1% | -11654.7% | LYRA |
| FY2024 | $0M | N/A | -6280.8% | N/A | LYRA |
| FY2025 | $0M | N/A | -7794.5% | N/A | LYRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
LYRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PLRX
UNCLASSIFIED
Current IV
12.8%
IV Percentile
4th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact PLRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
LYRA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PLRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ LYRA vs PLRX Key Questions & Quantitative Answers
As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (39.0/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus PLRX at $0.66 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (-100.0% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile PLRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LYRA leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with PLRX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), LYRA cumulative revenue shifted N/A while PLRX shifted -83.3%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLRX.
LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas PLRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus PLRX (-50.3% ROE) capital efficiency.
In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, PLRX carries 12.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.93β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PLRX vs LYRA · Reverse Pair
LYRA vs PASG
· Sector Peer
LYRA vs ORIC
· Sector Peer
LYRA vs KROS
· Sector Peer
PLRX vs PASG
· Sector Peer
PLRX vs ORIC
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem